journal article·2024

Penetration enhancers strengthen tough hydrogel bioadhesion and modulate locoregional drug delivery

Wenna Shi, Hui Xue, Tianwei Du, Jun-Li Liu, Victor Ling, Yuzhuo Wang, Zhenwei Ma, Zu-hua Gao

Biomaterials Science· Volume 12· Issue 21
Publisher page

Abstract

The human body possesses natural barriers, such as skin and mucosa, which limit the effective delivery of therapeutics and integration of medical devices to target tissues. Various strategies have been deployed to breach these barriers mechanically, chemically, or electronically. The development of various penetration enhancers (PEs) offers a promising solution due to their ability to increase tissue permeability using readily available reagents. However, existing PE-mediated delivery methods often rely on weak gel or liquid drug formulations, which are not ideal for sustained local delivery. Hydrogel adhesives that can seamlessly interface biological tissues with controlled drug delivery could potentially resolve these issues. Here, we demonstrate that tough adhesion between drug-laden hydrogels and biological tissue (e.g. skin and tumours) can lead to effective local delivery of drugs deep into targeted tissues by leveraging the enhanced tissue penetration mediated by PEs. The drug release profile of the hydrogel adhesives can be fine-tuned by further engineering the nanocomposite hydrogel matrix to elute chemotherapeutics from 2 weeks to 2 months. Using a 3D tumour spheroid model, we demonstrated that PEs increased the cancer-killing effectiveness of doxorubicin by facilitating its delivery into tumour microtissues. Therefore, the proposed tough bioadhesion and drug delivery strategy modulated by PEs holds promise as a platform technique to develop next-generation wearable and implantable devices for cancer management and regenerative medicine.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, Canada

Department of Pharmacy, Shandong Cancer Hospital and Institute, Jinan, China

Department of Experimental Medicine, BC Cancer Research Institute, Vancouver, Canada

School of Biomedical Engineering, University of British Columbia, Vancouver, Canada

Department of Medicine, McGill University Health Centre Research Institute, Montreal, Canada

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

Funding

Canadian Institutes of Health Research · Canada Foundation for Innovation · British Columbia Knowledge Development Fund

References (63)

Show source-provided references
1. Zhang · Mucosal Immunol. · 2022 · 15 · 55110.1038/s41385-022-00505-y ↗
2. Turner · Nat. Rev. Immunol. · 2009 · 9 · 79910.1038/nri2653 ↗
3. Yamauchi · J. Clin. Invest. · 2018 · 128 · 1610.1172/JCI93554 ↗
4. Naik · Matrix Biol. · 2023 · 119 · 12510.1016/j.matbio.2023.04.002 ↗
5. Prausnitz · Nat. Biotechnol. · 2008 · 26 · 126110.1038/nbt.1504 ↗
6. Mitragotri · Adv. Drug Delivery Rev. · 2013 · 65 · 10010.1016/j.addr.2012.07.016 ↗
7. Wermeling · Proc. Natl. Acad. Sci. U. S. A. · 2008 · 105 · 205810.1073/pnas.0710355105 ↗
8. Herndon · BMC Med. · 2004 · 2 · 1210.1186/1741-7015-2-12 ↗
9. Yang · Sci. Adv. · 2022 · 8 · eadd319710.1126/sciadv.add3197 ↗
10. Tang · Sci. Adv. · 2018 · 4 · eaat936510.1126/sciadv.aat9365 ↗
11. Ma · ACS Appl. Mater. Interfaces · 2019 · 11 · 4781010.1021/acsami.9b19906 ↗
12. Ma · Sci. Rep. · 2020 · 10 · 583710.1038/s41598-020-62659-8 ↗
13. Kalia · Adv. Drug Delivery Rev. · 2004 · 56 · 61910.1016/j.addr.2003.10.026 ↗
14. Karande · Nat. Biotechnol. · 2004 · 22 · 19210.1038/nbt928 ↗
15. Karande · Proc. Natl. Acad. Sci. U. S. A. · 2005 · 102 · 468810.1073/pnas.0501176102 ↗
16. Li · Nat. Rev. Mater. · 2016 · 1 · 1
17. Ma · Adv. Mater. Technol. · 2024 · 230159410.1002/admt.202301594 ↗
18. Li · Mater. Horiz. · 2023 · 10 · 170510.1039/D2MH01242A ↗
19. Bao · ACS Appl. Mater. Interfaces · 2021 · 13 · 3784910.1021/acsami.1c09231 ↗
20. Ma · Science · 2022 · 377 · 75110.1126/science.abn8699 ↗
21. Li · Science · 2017 · 357 · 37810.1126/science.aah6362 ↗
22. Ma · Sci. Adv. · 2021 · 7 · eabc301210.1126/sciadv.abc3012 ↗
23. Yang · Adv. Mater. · 2018 · 30 · 180067110.1002/adma.201800671 ↗
24. Borrás-Blasco · Int. J. Pharm. · 2004 · 269 · 12110.1016/j.ijpharm.2003.09.021 ↗
25. Mao · Pharm. Res. · 2012 · 29 · 218910.1007/s11095-012-0748-y ↗
26. Kauffman · React. Oxygen Species · 2016 · 2 · 432
27. Degerstedt · Drug Delivery Transl. Res. · 2024 · 14 · 97010.1007/s13346-023-01445-1 ↗
28. Li · Adv. Healthcare Mater. · 2018 · 7 · 170139310.1002/adhm.201701393 ↗
29. Huebsch · Proc. Natl. Acad. Sci. U. S. A. · 2014 · 111 · 976210.1073/pnas.1405469111 ↗
30. Yang · Mech. Mater. · 2021 · 157 · 10380010.1016/j.mechmat.2021.103800 ↗
31. Sun · Nature · 2012 · 489 · 13310.1038/nature11409 ↗
32. Lee · Nature · 2007 · 448 · 33810.1038/nature05968 ↗
33. Yang · Proc. Natl. Acad. Sci. U. S. A. · 2023 · 120 · e230781612010.1073/pnas.2307816120 ↗
34. Ghosh · J. Cosmet. Sci. · 2007 · 58 · 109
35. Nicolazzo · J. Pharm. Sci. · 2004 · 93 · 43110.1002/jps.10559 ↗
36. Yanase · Int. J. Cosmet. Sci. · 2018 · 40 · 4410.1111/ics.12430 ↗
37. Chen · J. Colloid Interface Sci. · 2022 · 608 · 40510.1016/j.jcis.2021.09.098 ↗
38. Ananthapadmanabhan · Int. J. Cosmet. Sci. · 2013 · 35 · 33710.1111/ics.12042 ↗
39. Salimi · Adv. Pharm. Bull. · 2022 · 13 · 96
40. Naik · J. Controlled Release · 1995 · 37 · 29910.1016/0168-3659(95)00088-7 ↗
41. Notman · Biophys. J. · 2007 · 93 · 205610.1529/biophysj.107.104703 ↗
42. Dahl · Contact Dermatitis · 1977 · 3 · 26310.1111/j.1600-0536.1977.tb03672.x ↗
43. Piret · J. Appl. Toxicol. · 2008 · 28 · 16410.1002/jat.1262 ↗
44. Qi · Adv. Funct. Mater. · 2020 · 30 · 200425710.1002/adfm.202004257 ↗
45. Shi · Adv. Healthcare Mater. · 2021 · 10 · 200145510.1002/adhm.202001455 ↗
46. Kumar · J. Controlled Release · 2015 · 199 · 16810.1016/j.jconrel.2014.12.006 ↗
47. Murphy · Commun. Biol. · 2022 · 5 · 110.1038/s42003-021-02997-z ↗
48. Abd El-Sadek · Sci. Rep. · 2023 · 13 · 1537710.1038/s41598-023-41846-3 ↗
49. Kuderer · Nat. Rev. Clin. Oncol. · 2022 · 19 · 68110.1038/s41571-022-00685-3 ↗
50. Lustberg · Nat. Rev. Clin. Oncol. · 2023 · 20 · 52710.1038/s41571-023-00776-9 ↗
51. Herrmann · Nat. Rev. Cardiol. · 2020 · 17 · 50310.1038/s41569-020-0347-2 ↗
52. Ma · Adv. Mater. · 2021 · 33 · 200766310.1002/adma.202007663 ↗
53. Finbloom · Adv. Drug Delivery Rev. · 2020 · 167 · 8910.1016/j.addr.2020.06.007 ↗
54. Zheng · Nat. Rev. Bioeng. · 2024 · 2 · 32410.1038/s44222-023-00141-6 ↗
55. Dul · J. Controlled Release · 2023 · 361 · 23610.1016/j.jconrel.2023.07.001 ↗
56. Zhang · J. Mater. Chem. B · 2022 · 10 · 605910.1039/D2TB00905F ↗
57. Ni · Proc. Natl. Acad. Sci. U. S. A. · 2023 · 120 · e221383712010.1073/pnas.2213837120 ↗
58. Goswami · Sci. Signaling · 2021 · 14 · eabd407710.1126/scisignal.abd4077 ↗
59. Tarbox · Drug Delivery Transl. Res. · 2018 · 8 · 182810.1007/s13346-017-0466-4 ↗
60. Yang · Nat. Commun. · 2013 · 4 · 170210.1038/ncomms2715 ↗
61. Priya · Expert Opin. Drug Delivery · 2006 · 3 · 12710.1517/17425247.3.1.127 ↗
62. Li · Acta Biomater. · 2021 · 121 · 34910.1016/j.actbio.2020.12.023 ↗
63. Wang · Small Sci. · 2023 · 3 · 230012610.1002/smsc.202300126 ↗